2020 RESEARCH
- Archives -MassBiologics announces partnership with PTC Therapeutics to manufacture gene therapy for rare pediatric condition
MassBiologics of UMass Medical School has entered into an agreement with PTC Therapeutics to manufacture biological investigational new drugs and commercial pharmaceutical products for use in humans.
UMMS researchers study attitudes toward potential COVID-19 vaccine
As many as four in 10 adults would refuse or hesitate to get a COVID-19 vaccine, according to a national survey, results of which were published in the Annals of Internal Medicine. Study co-authors Kimberly Fisher, MD, and Kathleen Mazor, EdD, say the findings indicate that health education outreach would be necessary to achieve widespread uptake of a safe and effective vaccine.
Boston Globe, CNN: UMass Medical School seeking to enroll diverse communities in COVID vaccine trial
Robert Finberg, MD, spoke with the Boston Globe and CNN about measures UMass Medical School has taken to reach a diverse population as it recruits for its involvement in the Pfizer/ BioNTech vaccine trail for COVID-19.
New awards from Massachusetts Life Sciences Center support women’s health research
Medical device research projects by Gopal Vijayaraghavan, MD, MPH, and Mary Rusckowski, PhD, are among 11 projects that have received a total of $8.3 million in capital funding awards from the Massachusetts Life Sciences Center.
UMMS researcher co-directs project to enhance diversity in biomedical sciences workforce
Mary Munson, PhD, is co-directing a first-of-its-kind national program to enhance diversity in the academic biomedical workforce, funded by a $1.3 million, five-year grant from the National Institutes of Health.
UMass Medical School announces participation and enrollment for vaccine trial candidate against COVID-19
UMass Medical School is enrolling healthy volunteers to take part in a Phase II/III clinical trial testing whether a messenger RNA vaccine candidate can prevent infection with the virus that causes COVID-19.
Genomic analysis reveals many species may be vulnerable to SARS-CoV-2
A new study from scientists at UMass Medical School and the University of California, Davis, reveals that humans are not the only species facing a potential threat from SARS-CoV-2, the novel coronavirus that causes COVID-19.
Massachusetts Life Sciences Center capital funding to support three programs at Medical School
The Massachusetts Life Sciences Center has announced more than $15 million in capital funding to support life sciences innovation, including awards for three projects at UMass Medical School.
New study: MassBiologics discovers antibodies that may protect against COVID-19
A new study by researchers at MassBiologics of UMass Medical School published in Nature Communications suggests that COVID specific IgA monoclonal antibodies may provide effective immunity in the respiratory system against the novel coronavirus—a potentially critical feature of an effective vaccine.
UMass Medical School granted five-year, $30 million Clinical and Translational Sciences Award
UMass Medical School will bring the UMass Center for Clinical and Translational Science to its next level of innovation and collaboration with the five-year, $30 million renewal of its Clinical and Translational Sciences Award from the National Institutes of Health.